Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADIGME phase IIb trial of Betalutin in relapsed anti-CD20-refractory follicular lymphoma
NL-OMON55476Phase 2Active, not recruiting
- Sponsor
- Nordic Nanovector ASA
- Start
- Nov 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium (177Lu) lilotomab satetraxetan in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Nordic Nanovector ASA. Primary endpoint: Overall response rate. Started Nov 2019; status: active, not recruiting.
02
Drugs
lutetium (177Lu) lilotomab satetraxetan
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON55476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55476.